TNFα blockade reduces GVHD mortality and morbidity. B6D2F1 mice received recombinant human TNFR:Fc (▴; n = 10) or control human Ig (•; n = 9) 100 μg/d intraperitoneally on days −2, −1, and 0 (0 is day of BMT) and then on alternate days up to day 14. (A) The percentage of survival: ▴ v •, P < .001 by Wilcoxon rank-test. (B) Clinical score: ▴ v •, P < .05 by Mann-Whitney U test from day 7 up to 35.